Physician profile
Nathaniel Readal
NPI 1275775025
$1,993.48
in general payments reported to CMS, 2019-2025
9 companies · $1,908 in 2025
The $1,908 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.00 · 2020: $5.00 · 2021: $24.38 · 2022: $25.00 · 2023: $15.18 · 2025: $1,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Travel and Lodging: $837 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.30 |
| Travel and Lodging | $836.74 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Profound Medical Corp. | $1,757.97 | 2025 | Tulsa-Pro |
| Astellas Pharma US INC | $114.89 | 2025 | Padcev |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Tolmar Pharmaceuticals, INC. | $25.00 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $20.56 | 2021 | |
| Boston Scientific Corporation | $16.00 | 2019 | |
| Axonics, INC. | $15.18 | 2023 | Axonics |
| Travere Therapeutics, INC. | $7.64 | 2020-2021 | |
| Ambu INC. | $1.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Readal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.